Pacritinib for COVID-19: real-time analysis

Download Image

Post

c19early.org

Pacritinib for COVID-19

1 study with 200 patients

Serious outcome risk

Pacritinib

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Pacritinib studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−28%

Mortality (1)−28%

RCTs (1)−28%

Late (1)−28%

00.511.5+

← Pacritinib
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Dec 5 2022	Cafardi et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.42918	Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19
Dec 5 2022	28% higher mortality (p=0.63), 25% lower progression (p=0.38), and 17% worse improvement (p=0.53). RCT 200 hospitalized patients with severe COVID-19 showing no significant differences with pacritinib.